WEST

End of Result Set

Generate Collection | Print

L10: Entry 1 of 1 File: PGPB Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187471
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187471 A1

TITLE: Novel telomerase

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	Epalinges	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Palo Alto	CA	US	
Harley, Calvin	Palo Alto	CA	US	
Andrews, William H.	Richmond		US	

US-CL-CURRENT: 435/6; 435/183, 435/254.2, 435/320.1, 435/69.1, 536/23.2

CLAIMS:

We claim:

1. A substantially purified peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 71, 73, 75, 77, 79, 82, 83, 83, 85, 86, and 101.

2. A purified, isolated polynucleotide sequence encoding the polypeptide of claim 1.

3. The polynucleotide sequence of claim 2, wherein said polynucleotide hybridizes specifically to telomerase sequences, wherein said telomerase sequences are selected from the group consisting of human, Euplotes aediculatus, Oxytricha, Schizosaccharomyces, and Saccharomyces telomerase sequences.

4. The polynucleotide sequence of claim 3, comprising the complement of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 70, 72, 74, 76, 78, 80, 81, and 100, and variants thereof.

5. A polynucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 66, 69, 80, and 81.

6. The polynucleotide sequence of claim 5, wherein said polynucleotide sequence is selected from the group consisting of SEQ ID NOS: 70, 72, 74, 76, 78, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 102, 103, 104, 105, 106, 107, 108, 109, and 110.

7. The polynucleotide sequence of claim 6, wherein said nucleotide sequence comprises a purified, synthetic nucleotide sequence having a length of about ten to fifty nucleotides.

8. A method for detecting the presence of polynucleotide sequences encoding at least a portion of human telomerase in a biological sample, comprising the steps of: a) providing: i) a biological sample suspected of containing nucleic acid corresponding

to the polynucleotide sequence of SEQ ID NO: 100; ii) the nucleotide sequence of SEQ ID NO: 100, or a fragment thereof; b) combining said biological sample with said nucleotide under conditions such that a hybridization complex is formed between said nucleic acid and said nucleotide; and c) detecting said hybridization complex.

9. The method of claim 8, wherein, said nucleic acid corresponding to the nucleotide sequence of SEQ ID NO: 100 is ribonucleic acid.

10. The method of claim 9, wherein said detected hybridization complex correlates with expression of the polynucleotide of SEQ ID NO: 100 in said biological sample.

11. The method of claim 8, wherein, said nucleic acid corresponding to the nucleotide sequence of SEQ ID NO: 100 is deoxyribonucleic acid.

12. The method of claim 11, wherein said detecting of said hybridization complex comprises conditions that permit the detection of alterations in the nucleotide of SEQ ID NO: 100 in said biological sample.

13. An antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the nucleotide of SEQ ID NO: 100.

14. A pharmaceutical composition comprising the antisense molecule of claim 13, and a pharmaceutically acceptable excipient.

15. The polynucleotide sequence of claim 4, wherein said nucleotide sequence is contained on a recombinant expression vector.

16. The polynucleotide sequence of claim 15, wherein said expression vector containing said nucleotide sequence is contained within a host cell.

17. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO: 101, the method comprising the steps of: a) culturing the host cell of claim 16, under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

18. A purified antibody which binds specifically to a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 101.

19. A pharmaceutical composition comprising the antibody of claim 18 and a pharmaceutically acceptable excipient.

20. A method for detecting the expression of human telomerase in a biological sample comprising the steps of: a) providing: i) a biological sample suspected of expressing human telomerase protein; and ii) the antibody of claim 18; b) combining said biological sample and said antibody under conditions such that an antibody:protein complex is formed; and c) detecting said complex wherein the presence of said complex correlates with the expression of said protein in said biological sample.

WEST

End of Result Set

☐ Generate Collection Print

L12: Entry 1 of 1 File: PGPB Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030009019
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030009019 A1

TITLE: NOVEL TELOMERASE

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
CECH, THOMAS R.	BOULDER	CO	US	
LINGNER, JOACHIM	EPALINGS	CO	CH	
NAKAMURA, TORU	BOULDER	CA	US	
CHAPMAN, KAREN B.	SAUSALITO	CA	US	
MORIN, GREGG B.	PALO ALTO	CA	US	
HARLEY, CALVIN B.	PALO ALTO	CA	US	
ANDREWS, WILLIAM H.	RICHMOND		US	

US-CL-CURRENT: 536/23.2; 435/183, 435/6, 530/350, 530/387.1

CLAIMS:

We claim:

1. A substantially purified peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:71, 73, 75, 77, 79, 82, 83, 83, 85, 86, and 101.

2. A purified, isolated polynucleotide sequence encoding the polypeptide of claim 1.

3. The polynucleotide sequence of claim 2, wherein said polynucleotide hybridizes specifically to telomerase sequences, wherein said telomerase sequences are selected from the group consisting of human, Euplotes aediculatus, Oxytricha, Schizosaccharomyces, and Saccharmyces telomerase sequences

4. The polynucleotide sequence of claim 3, comprising the complement of a nucleic acid sequence selected from the group consisting of SEQ ID NOS:70, 72, 74, 76, 78, 80, 81, and 100, and variants thereof.

5. A polynucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence selected from the group consisting of SEQ ID NOS:66, 69, 80, and 81.

6. The polynucleotide sequence of claim 5, wherein said polynucleotide sequence is selected from the group consisting of SEQ ID NOS:70, 72, 74, 76, 78, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 102, 103, 104, 105, 106, 107, 108, 109, and 110.

7. The polynucleotide sequence of claim 6, wherein said nucleotide sequence comprises a purified, synthetic nucleotide sequence having a length of about ten to fifty nucleotides.

8. A method for detecting the presence of polynucleotide sequences encoding at least a portion of human telomerase in a biological sample, comprising the steps of: a) providing: i) a biological sample suspected of containing nucleic acid corresponding

to the polynucleotide sequence of SEQ ID NO:100; ii) the nucleotide sequence of SEQ ID NO:100, or a fragment thereof; b) combining said biological sample with said nucleotide under conditions such that a hybridization complex is formed between said nucleic acid and said nucleotide; and c) detecting said hybridization complex.

9. The method of claim 8, wherein, said nucleic acid corresponding to the nucleotide sequence of SEQ ID NO:100 is ribonucleic acid.

10. The method of claim 9, wherein said detected hybridization complex correlates with expression of the polynucleotide of SEQ ID NO:100 in said biological sample.

11. The method of claim 8, wherein, said nucleic acid corresponding to the nucleotide sequence of SEQ ID NO:100 is deoxyribonucleic acid.

12. The method of claim 11, wherein said detecting of said hybridization complex comprises conditions that permit the detection of alterations in the nucleotide of SEQ ID NO:100 in said biological sample.

13. An antisense molecule comprising the nucleic acid sequence complementary to at least a portion of the nucleotide of SEQ ID NO:100.

14. A pharmaceutical composition comprising the antisense molecule of claim 13, and a pharmaceutically acceptable excipient.

15. The polynucleotide sequence of claim 4, wherein said nucleotide sequence is contained on a recombinant expression vector.

16. The polynucleotide sequence of claim 15, wherein said expression vector containing said nucleotide sequence is contained within a host cell.

17. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:101, the method comprising the steps of: a) culturing the host cell of claim 16, under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

18. A purified antibody which binds specifically to a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:101.

19. A pharmaceutical composition comprising the antibody of claim 18 and a pharmaceutically acceptable excipient.

20. A method for detecting the expression of human telomerase in a biological sample comprising the steps of: a) providing: i) a biological sample suspected of expressing human telomerase protein; and ii) the antibody of claim 18; b) combining said biological sample and said antibody under conditions such that an antibody:protein complex is formed; and c) detecting said complex wherein the presence of said complex correlates with the expression of said protein in said biological sample.

WEST

End of Result Set

☐ Generate Collection Print

L16: Entry 1 of 1 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096344
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096344 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	PI. Croix-Blanche 25	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	
Andrews, William H.	Richmond		US	

US-CL-CURRENT: 435/69.1; 424/146.1, 435/199, 435/320.1, 435/325

CLAIMS:

What is claimed is:

1. A pharmaceutical composition suitable for administration to a human, comprising either: a) a polypeptide containing at least 8 contiguous amino acid residues in SEQ. ID NO:2; b) a polypeptide containing an amino acid sequence that is at least 90% identical to 20 contiguous amino acids in SEQ. ID NO:2; or c) a polynucleotide encoding either of the aforesaid polypeptides; in a pharmaceutically compatible carrier.

2. The pharmaceutical composition of claim 1, comprising a polypeptide containing at least 8 contiguous amino acid residues in SEQ. ID NO:2.

3. The pharmaceutical composition of claim 1, comprising a polypeptide containing an amino acid sequence that is at least 90% identical to 20 contiguous amino acids in SEQ. ID NO:2.

4. The pharmaceutical composition of claim 1, comprising a polynucleotide that encodes a polypeptide containing at least 8 contiguous amino acid residues in SEQ. ID NO:2.

5. The pharmaceutical composition of claim 1, comprising a polynucleotide that encodes a polypeptide containing an amino acid sequence that is at least 90% identical to 20 contiguous amino acids in SEQ. ID NO:2.

6. The pharmaceutical composition of claim 3, wherein the polypeptide contains at least 20 contiguous amino acid residues in SEQ. ID NO:2.

7. The pharmaceutical composition of claim 4, wherein the polypeptide contains at least 20 contiguous amino acid residues in SEQ. ID NO:2.

8. The pharmaceutical composition of claim 3, wherein the polypeptide contains at

least 50 contiguous amino acid residues in SEQ. ID NO:2.

9. The pharmaceutical composition of claim 4, wherein the polypeptide contains at least 50 contiguous amino acid residues in SEQ. ID NO:2.

10. The pharmaceutical composition of claim 1, further comprising an adjuvant.

11. A method for eliciting an immune response to human telomerase reverse transcriptase in a subject, comprising administering to the subject the composition of claim 1.

12. A method for eliciting an immune response to human telomerase reverse transcriptase in a subject, comprising administering to the subject the composition of claim 2.

13. A method for eliciting an immune response to human telomerase reverse transcriptase in a subject, comprising administering to the subject the composition of claim 3.

14. A method for eliciting an immune response to human telomerase reverse transcriptase in a subject, comprising administering to the subject the composition of claim 4.

15. A method for eliciting an immune response to human telomerase reverse transcriptase in a subject, comprising administering to the subject the composition of claim 5.

16. The method of claim 11, wherein the composition elicits an antibody response specific for telomerase reverse transcriptase.

17. The method of claim 11, wherein the composition elicits a cytotoxic T cell response specific for telomerase reverse transcriptase.

18. The method of claim 11, further comprising assessing whether a telomerase-specific immune response is produced as a result of the administration.

19. The composition of claim 1, in an amount wherein said peptide or protein is effective for eliciting an immunological response specific for telomerase reverse transcriptase.

20. The composition of claim 1, packaged in a container along with an indication of how the composition is to be administered.

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
20030059787	1

Database:
- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search: L23

Refine Search

Recall Text | Clear

Search History

DATE: Wednesday, November 19, 2003 Printable Copy Create Case

claims seen

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB; PLUR=YES; OP=OR			
L23	20030059787	1	L23
L22	20030059787	1	L22
L21	20030044953	1	L21
L20	20030032075	1	L20
DB=USPT; PLUR=YES; OP=OR			
L19	6093809	14	L19
L18	6093809	14	L18
DB=PGPB; PLUR=YES; OP=OR			
L17	20030100093	1	L17
L16	20030096344	1	L16
L15	20030044953	1	L15
L14	20030032075	1	L14
DB=USPT; PLUR=YES; OP=OR			
~~L13~~	~~20030032075~~	~~0~~	~~L13~~
DB=PGPB; PLUR=YES; OP=OR			
L12	20030009019	1	L12
L11	20030009011	1	L11
L10	20020187471	1	L10
DB=USPT; PLUR=YES; OP=OR			
~~L9~~	~~20020187471~~	~~0~~	~~L9~~
DB=PGPB; PLUR=YES; OP=OR			
L8	20020164786	1	L8
L7	20020164786A1	0	L7
L6	US20020164786A1	0	L6
L5	L4	0	L5
DB=USPT; PLUR=YES; OP=OR			
L4	US20020164786A1	0	L4
L3	L2	0	L3
L2	20020164786	0	L2
DB=PGPB; PLUR=YES; OP=OR			
L1	20020164786A1	0	L1

END OF SEARCH HISTORY